Paediatric Solid Tumour Biology and Therapeutics Group

Professor Louis Chesler’s group is investigating the genetic causes for the childhood cancers, neuroblastoma, medulloblastoma and rhabdomyosarcoma. 

Research, projects and publications in this group

Our group's aim is to improve the treatment and survival of children with neuroblastoma, medulloblastoma and rhabdomyosarcoma.

The goal of our laboratory is to improve the treatment and survival of children with neuroblastoma, medulloblastoma and rhabdomyosarcoma, three paediatric solid tumours in which high-risk patient cohorts can be defined by alterations in a single oncogene. We focus on the role of the MYCN oncogene, since aberrant expression of MYCNis very significantly associated with high-risk in all three diseases and implies that they may have a common cell-of-origin.

Elucidating the molecular signalling pathways that control expression of the MYCN oncoprotein and targeting these pathways with novel therapeutics is a major goal of the laboratory. We use a variety of innovative preclinical drug development platforms for this purpose.

Technologically, we focus on genetically engineered cancer models incorporating novel imaging (optical and fluorescent) modalities that can be used as markers to monitor disease progression and therapeutic response.

Our group has several key objectives:

  • Mechanistically dissect the role of the MYCN oncogene, and other key oncogenic driver genes in poor-outcome paediatric solid tumours (neuroblastoma, medulloblastoma, rhabdomyosarcoma).
  • Develop novel therapeutics targeting MYCN oncoproteins and other key oncogenic drivers
  • Develop improved genetic cancer models dually useful for studies of oncogenesis and preclinical development of novel therapeutics.
  • Use such models to develop and functionally validate optical imaging modalities useful as surrogate markers of tumour progression in paediatric cancer.

Professor Louis Chesler

Clinical Senior Lecturer/Group Leader:

Paediatric Solid Tumour Biology and Therapeutics Professor Louis Chesler (Profile pic)

Professor Louis Chesler is working to understand the biology of children’s cancers and use that information to discover and develop new personalised approaches to cancer treatment. His work focuses on improving the understanding of the role of the MYCN oncogene.

Researchers in this group

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6124

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 3617

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4186

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 3501

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4361

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6118

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6021

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6196

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6258

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6121

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4527

Email: [email protected]

Location: Sutton

.

OrcID: 0000-0003-3977-7020

Phone: +44 20 3437 6109

Email: [email protected]

Location: Sutton

I obtained an MSci in Biochemistry from the University of Glasgow in 2018. In October 2018 I joined the labs of Dr Michael Hubank and Professor Andrea Sottoriva to investigate the use of liquid biopsy to monitor clonal frequency and emergence of resistance mutations in paediatric cancers.

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6358

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6131

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

Professor Louis Chesler's group have written 113 publications

Most recent new publication 4/2025

See all their publications

Vacancies in this group

Working in this group

Postdoctoral Training Fellow

  • Chelsea
  • Structural Biology
  • Salary Range: £45,600 - £55,000 per annum
  • Fixed term

Under the leadership of Claudio Alfieri, we are seeking to appoint a Postdoctoral Training Fellow to join the Molecular Mechanisms of Cell Cycle Regulation Group at the Chester Beatty Laboratories, Fulham Road in London. This project aims to investigate the molecular mechanisms of cell cycle regulation by macromolecular complexes involved in cell proliferation decisions, by combining genome engineering, proteomics and in situ structural biology. For general information on Post Doc's at The ICR can be found here. Key Requirements The successful candidate must have a PhD in cellular biochemistry and experience in Cryo-EM and CLEM is desirable. The ICR has a workforce agreement stating that Postdoctoral Training Fellows can only be employed for up to 7 years as PDTF at the ICR, providing total postdoctoral experience (including previous employment at this level elsewhere) does not exceed 7 years Department/Directorate Information: The candidate will work in the Molecular Mechanisms of Cell Cycle Regulation Group within the ICR Division of Structural Biology headed by Prof. Laurence Pearl and Prof. Sebastian Guettler. The division has state-of-the-art facilities for protein expression and biophysics/x-ray crystallography, in particular the Electron Microscopy Facility is equipped with a Glacios 200kV with Falcon 4i detector with Selectris energy filter and the ICR has access to Krios microscopes via eBIC and the LonCEM consortium. We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Claudio Alfieri via Email on [email protected]

Higher Scientific Officer - Drug Discovery Biology, Centre for Protein Degradation

  • Sutton
  • Cancer Therapeutics
  • £39,805 - £49,023
  • Fixed term

We are seeking to recruit a Higher Scientific Officer within the Induced Proximity Therapeutics (IPT) Team in the ICR Centre for Protein Degradation to support our molecular glue and PROTAC drug discovery projects and expand induced proximity technology. The IPT team focuses on three main areas of research: Cancer target validation Screening, profiling and molecular mechanism of action of molecular glue and PROTAC degraders Novel E3 ligase biology and ligand discovery The successful candidate will work in a multidisciplinary team and play a key role in target validation, developing in vitro and cell-based assays, and pharmacological characterisation of novel molecular glue degraders and PROTACs, but may also contribute to other activities. About you The successful candidate: Will be a strong team player who is technically minded and passionate about science and cancer drug discovery Will hold a first degree, and preferably a PhD, in biological science or biochemistry Will have experience in cancer biology/target validation, genetic manipulation techniques, in vitro and cell-based assay development and pharmacological compound profiling Experience in targeted protein degradation will be a significant advantage. Department/Directorate Information This position will be based in the ICR's Centre for Protein Degradation, a part of the Centre for Cancer Drug Discovery (CCDD) specialising in developing novel drug modalities that re-wire tumour cells' signalling by targeted degradation of key oncogenic drivers. Our experienced biologists work closely with medicinal chemists, biophysicists, computational scientists, oncology specialists and physicians on discovering new medicines - molecular glue degraders and PROTACs - using innovative screening platforms and characterising their mechanisms of action, as well as expanding the repertoire of novel degradable drug targets and E3 ligases (enzymes that mediate protein degradation). Our research provides a nucleus for the academics and pharmaceutical industry to explore therapeutic potential of targeted protein degradation from laboratory hypothesis-testing to early clinical trials, for the benefit of cancer patients. What we offer A dynamic and supportive research environment in one of the successful academic cancer drug discovery centres in the UK Access to state-of-the-art facilities and professional development Collaboration with leading drug discovery and oncology scientist Competitive salary and pension To learn more about this role, please download the attached job pack. For informal inquiries, please contact Dr Agnieszka Konopacka, Group Leader, Induced Proximity Therapeutics, Centre for Protein Degradation via email: [email protected].

Industrial partnership opportunities with this group

Opportunity: A novel test for predicting future cancer risk in patients with inflammatory bowel disease

Commissioner: Professor Trevor Graham

Recent discoveries from this group

30/04/25

Scientists have worked out how a protective element of our DNA helps prevent an abnormal genetic event that can lead to cells becoming cancerous.

They have shown exactly how telomeres – the protective caps that sit at the end of chromosomes – stop these thread-like structures from fusing together, which can cause harmful DNA rearrangements. By uncovering how this fusion is usually prevented, the researchers have moved a step closer towards determining how and why things can sometimes go wrong.

Through this work, the team has not only provided an explanation for previous findings in this area of research but also potentially opened the door to finding new ways to stop cancer from developing.

Researchers at The Institute of Cancer Research, London, led the study, which was primarily funded by Cancer Research UK. The findings were published in the journal Nature.

Telomeres have an important role

Telomeres are often compared to the plastic tips on shoelaces, where the laces represent chromosomes. Consisting of repeated sequences of nucleotides – the building blocks of DNA – they shield the ends of chromosomes from damage and help ensure that all of the DNA is replicated during cell division.

By clearly marking the ends of chromosomes, telomeres prevent them from being recognised as broken DNA. This could trigger DNA repair processes that result in chromosome fusion or lead to other genetic abnormalities. The risk of these changes, referred to as genomic instability, is associated with the development of cancer.

The fact that telomeres are central to many aspects of cancer means that scientists have long been interested in their role and what happens when they become defective.

Although previous studies had already demonstrated that telomeres block chromosome fusion through a process called classical non-homologous end joining (cNHEJ), it was not apparent how this was achieved. The scientists behind the new study decided to search for the answer.

Combining complementary techniques

Rather than using a completely new method, the team applied a range of different techniques to help them acquire the information needed. These included an innovative approach called reconstitution biochemistry, in which scientists assemble a small set of molecular components outside of the cell to recreate specific processes that occur inside it.

It was already known that cNHEJ is initiated when an enzyme called DNA-dependent protein kinase (DNA-PK) binds with the telomeres and various proteins. This study revealed that two proteins called RAP1 and TRF2 form a complex with DNA-PK to prevent cNHEJ from taking place. It also showed that this only occurs at the telomeres.

Additional processes must happen at telomeres for them to properly protect the chromosome ends from other DNA repair processes, and the researchers have already started working on identifying and understanding them.

A simple solution

First author Dr Patrik Eickhoff, a Postdoctoral Training Fellow in the Division of Cell and Molecular Biology at The Institute of Cancer Research (ICR), said:

“We are delighted to be able to provide a molecular explanation for how individual chromosomes are maintained in human cells. Blocking DNA-PK from working at telomeres stops chromosomes from fusing, preventing the genome from becoming extensively rearranged – a hallmark of the early stages of cancer.

“We hope this information will help us further our understanding of how cancer develops, which is crucial for developing new treatments.”

Senior author Dr Max Douglas, Group Leader of the Telomere Biology Group at the ICR, said:

“This study helps answer a fundamental question in chromosome biology and provides an explanation for previous findings in this field of research.

“Because of its ability to fuse different chromosomes, cNHEJ represents a major threat to stable chromosomes in human cells. We were surprised by the neat mechanism that these cells have evolved to solve the problem of how to stop cNHEJ at telomeres and how simple the solution is. It is elegant in its simplicity."